Physician profile
Michael L Powell
NPI 1497104442
$2,810.30
in general payments reported to CMS, 2019-2025
38 companies · $628 in 2025
The $628 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.28 · 2020: $34.75 · 2021: $15.34 · 2022: $95.15 · 2023: $905 · 2024: $1,073 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.98 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $415.49 | 2024 | |
| Novo Nordisk INC | $170.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $131.46 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $121.17 | 2023-2024 | |
| Amgen INC. | $111.88 | 2022-2024 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $108.07 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $107.85 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $106.48 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $104.66 | 2023-2024 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $92.80 | 2024 | Edarbi |
| Lilly USA, LLC | $79.47 | 2023-2025 | Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.03 | 2023-2025 | Xifaxan |
| Dermira, INC. | $47.30 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.12 | 2025 | Caplyta |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $42.19 | 2023 | Flexible Guide Pin (Stryker Acl Versitomic), Alphavent, Iconix |
| Ascensia Diabetes Care US INC. | $36.18 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $32.50 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.71 | 2022-2025 | |
| Mylan Specialty L.P. | $30.19 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $30.19 | 2023-2024 | Trintellix |
| Impel Pharmaceuticals INC. | $29.81 | 2023 | Trudhesa |
| Janssen Pharmaceuticals, INC | $28.67 | 2023-2024 | Invega Sustenna |
| Lundbeck LLC | $28.12 | 2023 | Vyepti |
| Nalu Medical, INC. | $26.75 | 2025 | Nalu Neurostimulation System |
| Biohaven Pharmaceutical Holding Company LTD. | $24.17 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.63 | 2025 | Keveyis |
| Sanofi Pasteur INC. | $19.64 | 2020 | |
| Organon LLC | $17.91 | 2023 | |
| Medtronic, INC. | $17.13 | 2024 | Kyphon Express II Kyphopak Tray |
| Glaxosmithkline, LLC. | $15.11 | 2020 | |
| Coopersurgical, INC. | $14.90 | 2025 | Paragard T 380a |
| Axsome Therapeutics, INC. | $14.85 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.78 | 2024 | Uptravi, Opsumit |
| Phathom Pharmaceuticals, INC. | $13.61 | 2025 | Voquezna |
| Ardelyx, INC. | $13.55 | 2024 | Ibsrela |
| Dexcom, INC. | $12.70 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.